Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia

The phase II study of tirabrutinib monotherapy at a daily dose of 480 mg under fasting conditions for treatment‐naïve and relapsed/refractory Waldenström's macroglobulinemia (ONO‐4059‐05 study) demonstrated a promising efficacy and tolerable safety profile. We conducted an unplanned analysis wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekiguchi, Naohiro, Rai, Shinya, Munakata, Wataru, Suzuki, Kenshi, Handa, Hiroshi, Shibayama, Hirohiko, Endo, Tomoyuki, Terui, Yasuhito, Iwaki, Noriko, Fukuhara, Noriko, Tatetsu, Hiro, Iida, Shinsuke, Ishikawa, Takayuki, Iguchi, Daisuke, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207369/
https://www.ncbi.nlm.nih.gov/pubmed/35332633
http://dx.doi.org/10.1111/cas.15344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207369/
https://www.ncbi.nlm.nih.gov/pubmed/35332633
http://dx.doi.org/10.1111/cas.15344

Ejemplares similares